Publications
Detailed Information
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Cited 19 time in
Web of Science
Cited 26 time in Scopus
- Authors
- Issue Date
- 2018-05
- Citation
- Breast Cancer, Vol.25 No.3, pp.370-374
- Abstract
- This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/metastatic breast cancer and <= 3 prior chemotherapies were randomized 1:1 to eribulin mesilate 1.4 mg/m(2) intravenously on days 1 and 8, or twice-daily oral capecitabine 1.25 g/m(2) on days 1-14 (21-day cycles). This analysis included 392 patients. Median overall survival was longer in patients receiving eribulin compared with capecitabine (16.1 vs 13.5 months, respectively; HR 0.77, P = 0.026). Median progression-free survival and response rates were similar between arms. Both treatments had manageable safety profiles.
- ISSN
- 1340-6868
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.